BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M, Sugiyama Y. Phase 0/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov 2020;19:801-18. [PMID: 32901140 DOI: 10.1038/s41573-020-0080-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Greenwood JC, Talebi FM, Jang DH, Spelde AE, Tonna JE, Gutsche JT, Horak J, Acker MA, Kilbaugh TJ, Shofer FS, Augoustides JGT, Bakker J, Brenner JS, Muzykantov VR, Abella BS. Topical nitroglycerin to detect reversible microcirculatory dysfunction in patients with circulatory shock after cardiovascular surgery: an observational study. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-19741-0] [Reference Citation Analysis]
2 Breuil L, Goutal S, Marie S, Del Vecchio A, Audisio D, Soyer A, Goislard M, Saba W, Tournier N, Caillé F. Comparison of the Blood–Brain Barrier Transport and Vulnerability to P-Glycoprotein-Mediated Drug–Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging. Pharmaceutics 2022;14:1658. [DOI: 10.3390/pharmaceutics14081658] [Reference Citation Analysis]
3 Acar S, Nieblas-Bedolla E, Armstrong AE, Hirbe AC. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses. Pediatr Neurol 2022;134:1-6. [PMID: 35759947 DOI: 10.1016/j.pediatrneurol.2022.06.003] [Reference Citation Analysis]
4 Weimer MB, Fiellin DA. Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication? Addiction 2022;117:1507-9. [PMID: 35032081 DOI: 10.1111/add.15799] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Mellinghoff IK, Cloughesy TF. Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. J Clin Oncol 2022;:JCO2102166. [PMID: 35201903 DOI: 10.1200/JCO.21.02166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Luginbuehl V, Abraham E, Kovar K, Flaaten R, Müller AM. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv 2022;:107917. [PMID: 35149146 DOI: 10.1016/j.biotechadv.2022.107917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Oesterreicher Z, Eberl S, Wulkersdorfer B, Matzneller P, Eder C, van Duijn E, Vaes WHJ, Reiter B, Stimpfl T, Jäger W, Nussbaumer-Proell A, Marhofer D, Marhofer P, Langer O, Zeitlinger M. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clin Pharmacokinet 2022. [PMID: 34997559 DOI: 10.1007/s40262-021-01091-1] [Reference Citation Analysis]
8 Kandi V, Suvvari TK, Vadakedath S, Godishala V. Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives. Borneo J Pharm 2021;4:311-23. [DOI: 10.33084/bjop.v4i4.2571] [Reference Citation Analysis]
9 Chen Y, Xiang X, Qi R, Wang Y, Huang Y, You M, Xian Y, Wu Y, Fu R, Kang C, Tang J, Yu H, Zhang T, Yuan Q, Luo W, Xia N. Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice. Antib Ther 2021;4:197-207. [PMID: 34646979 DOI: 10.1093/abt/tbab020] [Reference Citation Analysis]
10 de Las Heras B, Bouyoucef-Cherchalli D, Reeve L, Reichl A, Mandarino D, Flach S, Vidal L, van Brummelen EMJ, Steeghs N. Healthy volunteers in first-in-human oncology drug development for small molecules. Br J Clin Pharmacol 2021. [PMID: 34558113 DOI: 10.1111/bcp.15092] [Reference Citation Analysis]
11 Le Fur M, Ross A, Pantazopoulos P, Rotile N, Zhou I, Caravan P, Medarova Z, Yoo B. Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer. Cancer Nanotechnol 2021;12:16. [PMID: 34531932 DOI: 10.1186/s12645-021-00089-5] [Reference Citation Analysis]
12 Chi LH, Burrows AD, Anderson RL. Can preclinical drug development help to predict adverse events in clinical trials? Drug Discov Today 2021:S1359-6446(21)00370-6. [PMID: 34469805 DOI: 10.1016/j.drudis.2021.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xue R, Li R, Wang J, Tong W, Hao J. Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review. J Clin Transl Hepatol 2021;9:559-67. [PMID: 34447686 DOI: 10.14218/JCTH.2021.00007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lang J, Vincent L, Chenel M, Ogungbenro K, Galetin A. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. Eur J Pharm Sci 2021;165:105932. [PMID: 34260894 DOI: 10.1016/j.ejps.2021.105932] [Reference Citation Analysis]
15 Lee EQ. Clinical Trial Considerations in Neuro-oncology. Curr Treat Options Oncol 2021;22:78. [PMID: 34213625 DOI: 10.1007/s11864-021-00875-8] [Reference Citation Analysis]
16 Koyama S, Toshimoto K, Lee W, Aoki Y, Sugiyama Y. Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. Drug Metab Dispos 2021;49:298-304. [PMID: 33558262 DOI: 10.1124/dmd.120.000023] [Reference Citation Analysis]
17 Berdel WE, Harrach S, Brand C, Brömmel K, Berdel AF, Hintelmann H, Schliemann C, Schwöppe C. Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans? Cancers (Basel) 2020;12:E3536. [PMID: 33256235 DOI: 10.3390/cancers12123536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]